

IgA Nephropathy Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/IBC8DFAC5250EN.html>

Date: June 2025

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: IBC8DFAC5250EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days. Market Lifecycle Stage

The global IgA nephropathy market is currently in the growth stage of its lifecycle, driven by increasing awareness, improved diagnostic capabilities, and advancements in renal treatment options. The market is expanding as novel therapies, such as complement inhibitors and non-immunosuppressive drugs, are gaining traction, addressing the unmet need for more effective renal treatments. With ongoing research and development, pharmaceutical companies are investing heavily in clinical trials to bring new, targeted therapies to market. Additionally, regulatory bodies are accelerating the approval process for innovative renal drugs, further fueling market growth. Despite this positive momentum, challenges such as high treatment costs and the variability in disease progression may hinder rapid expansion. As a result, the market is expected to continue growing, although competition and price pressures will likely intensify as more treatments emerge.

Impact

Increasing demand for IgA nephropathy therapies is anticipated to support the growth of the global IgA nephropathy market during the forecast period 2025-2035.

The global IgA nephropathy market is expected to grow at a significant rate

due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

North America is expected to dominate the global IgA nephropathy market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global IgA nephropathy market.

Recent Developments

Regulatory Activities: In April 2025, the U.S. FDA granted accelerated approval for Novartis' Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy.

Partnerships: In March 2025, Folia Health and Novartis Pharmaceuticals, Inc. announced their collaboration on an innovative at-home observational real-world evidence initiative aimed at supporting individuals with IgA nephropathy.

Regulatory Activities: In November 2024, South Korea approved Everest Medicines' NEFECON for the treatment of primary IgA nephropathy.

Regulatory Activities: In September 2024, Ligand partner Travele Therapeutics received FDA approval for FILSPARI (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in IgA nephropathy.

Demand – Drivers and Limitations

Drivers:

Increasing Prevalence of IgA Nephropathy

Continuous Advancements in Treatment Options

Improved Diagnosis and Awareness

Challenges:

High Treatment Costs

Limited Awareness in Developing Markets

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global IgA nephropathy market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Novartis, and Travele Therapeutics, Inc., have been involved in the development of therapies for IgA nephropathy.

Competitive Strategy: Enterprises led by market leaders in the global IgA nephropathy market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Novartis

F. Hoffmann-La Roche

Ionis Pharmaceuticals

Vertex Pharmaceuticals

Otsuka Pharmaceutical

Biogen

Arrowhead Pharmaceuticals

NovelMed

Q32 Bio

Walden Biosciences

Takeda Pharmaceutical

Vera Therapeutics

Biocity Biopharmaceutics Co., Ltd.

Calliditas Therapeutics AB

Traverse Therapeutics, Inc.

Alexion Pharmaceuticals, Inc.

Contents

Executive Summary

Scope of Study

1. GLOBAL IGA NEPHROPATHY MARKET: MARKET OUTLOOK

1.1 Industry Outlook

1.1.1 Market Overview and Ecosystem

1.1.2 Market Trends

1.1.3 Epidemiological Analysis of IgA Nephropathy

1.1.3.1 By Region

1.1.3.1.1 U.S.

1.1.3.1.2 EU5

1.1.3.1.3 Rest-of-the-World

1.1.4 Clinical Trials

1.1.4.1 By Phase

1.1.4.2 By Sponsor Type

1.1.5 Regulatory Landscape / Compliance

1.1.5.1 Legal Requirement and Framework in the U.S.

1.1.5.2 Legal Requirement and Framework in the E.U.

1.1.5.3 Legal Requirement and Framework in Asia-Pacific

1.1.5.4 Legal Requirement and Framework in Rest-of-the-World

1.2 Market Dynamics

1.2.1 Impact Analysis

1.2.2 Market Drivers

1.2.3 Market Restraints

1.2.4 Market Opportunities

2. GLOBAL IGA NEPHROPATHY MARKET (BY REGION), \$MILLION, 2023-2035

2.1 North America

2.1.1 Key Findings

2.1.2 Market Dynamics

2.1.3 Market Sizing and Forecast

2.1.3.1 North America IgA Nephropathy Market (by Country)

2.1.3.1.1 U.S.

2.1.3.1.2 Canada

2.2 Europe

- 2.2.1 Key Findings
- 2.2.2 Market Dynamics
- 2.2.3 Market Sizing and Forecast
 - 2.2.3.1 Europe IgA Nephropathy Market (by Country)
 - 2.2.3.1.1 U.K.
 - 2.2.3.1.2 Germany
 - 2.2.3.1.3 France
 - 2.2.3.1.4 Italy
 - 2.2.3.1.5 Spain
 - 2.2.3.1.6 Rest-of-Europe

2.3 Asia-Pacific

- 2.3.1 Key Findings
- 2.3.2 Market Dynamics
- 2.3.3 Market Sizing and Forecast
 - 2.3.3.1 Asia-Pacific IgA Nephropathy Market (by Country)
 - 2.3.3.1.1 Japan
 - 2.3.3.1.2 China
 - 2.3.3.1.3 Rest-of-Asia-Pacific

2.4 Rest-of-the-World

- 2.4.1 Key Findings
- 2.4.2 Market Dynamics
- 2.4.3 Market Sizing and Forecast

3. GLOBAL IGA NEPHROPATHY MARKET - COMPETITIVE BENCHMARKING AND COMPANY PROFILES

3.1 Competitive Landscape

- 3.1.1 Key Strategies and Developments by Company
 - 3.1.1.1 Funding Activities
 - 3.1.1.2 Mergers and Acquisitions
 - 3.1.1.3 Regulatory Approvals
 - 3.1.1.4 Partnerships, Collaborations and Business Expansions
- 3.1.2 Key Developments Analysis

3.2 Company Profiles

- 3.2.1 Novartis
 - 3.2.1.1 Company Overview
 - 3.2.1.2 Product Portfolio
 - 3.2.1.3 Target Customers/End Users
 - 3.2.1.4 Analyst View

- 3.2.2 F. Hoffmann-La Roche
 - 3.2.2.1 Company Overview
 - 3.2.2.2 Product Portfolio
 - 3.2.2.3 Target Customers/End Users
 - 3.2.2.4 Analyst View
- 3.2.3 Ionis Pharmaceuticals
 - 3.2.3.1 Company Overview
 - 3.2.3.2 Product Portfolio
 - 3.2.3.3 Target Customers/End Users
 - 3.2.3.4 Analyst View
- 3.2.4 Vertex Pharmaceuticals
 - 3.2.4.1 Company Overview
 - 3.2.4.2 Product Portfolio
 - 3.2.4.3 Target Customers/End Users
 - 3.2.4.4 Analyst View
- 3.2.5 Otsuka Pharmaceutical
 - 3.2.5.1 Company Overview
 - 3.2.5.2 Product Portfolio
 - 3.2.5.3 Target Customers/End Users
 - 3.2.5.4 Analyst View
- 3.2.6 Biogen
 - 3.2.6.1 Company Overview
 - 3.2.6.2 Product Portfolio
 - 3.2.6.3 Target Customers/End Users
 - 3.2.6.4 Analyst View
- 3.2.7 Arrowhead Pharmaceuticals
 - 3.2.7.1 Company Overview
 - 3.2.7.2 Product Portfolio
 - 3.2.7.3 Target Customers/End Users
 - 3.2.7.4 Analyst View
- 3.2.8 NovelMed
 - 3.2.8.1 Company Overview
 - 3.2.8.2 Product Portfolio
 - 3.2.8.3 Target Customers/End Users
 - 3.2.8.4 Analyst View
- 3.2.9 Q32 Bio
 - 3.2.9.1 Company Overview
 - 3.2.9.2 Product Portfolio
 - 3.2.9.3 Target Customers/End Users

- 3.2.9.4 Analyst View
- 3.2.10 Takeda Pharmaceutical
 - 3.2.10.1 Company Overview
 - 3.2.10.2 Product Portfolio
 - 3.2.10.3 Target Customers/End Users
 - 3.2.10.4 Analyst View
- 3.2.11 Vera Therapeutics
 - 3.2.11.1 Company Overview
 - 3.2.11.2 Product Portfolio
 - 3.2.11.3 Target Customers/End Users
 - 3.2.11.4 Analyst View
- 3.2.12 Biocity Biopharmaceutics Co., Ltd.
 - 3.2.12.1 Company Overview
 - 3.2.12.2 Product Portfolio
 - 3.2.12.3 Target Customers/End Users
 - 3.2.12.4 Analyst View
- 3.2.13 Calliditas Therapeutics AB
 - 3.2.13.1 Company Overview
 - 3.2.13.2 Product Portfolio
 - 3.2.13.3 Target Customers/End Users
 - 3.2.13.4 Analyst View
- 3.2.14 Traveře Therapeutics, Inc.
 - 3.2.14.1 Company Overview
 - 3.2.14.2 Product Portfolio
 - 3.2.14.3 Target Customers/End Users
 - 3.2.14.4 Analyst View
- 3.2.15 Alexion Pharmaceuticals, Inc.
 - 3.2.15.1 Company Overview
 - 3.2.15.2 Product Portfolio
 - 3.2.15.3 Target Customers/End Users
 - 3.2.15.4 Analyst View

4. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Global IgA Nephropathy Market, Market Overview

Figure: Global IgA Nephropathy Market, Epidemiological Analysis, U.S.

Figure: Global IgA Nephropathy Market Coverage

Figure: Global IgA Nephropathy Market Key Trends, Impact Analysis, 2023-2035

Figure: Global IgA Nephropathy Market, Competitive Landscape, January 2022-April 2025

List Of Tables

LIST OF TABLES

Table: Global IgA Nephropathy Market, Regulatory Scenario

Table: Global IgA Nephropathy Market Dynamics, Impact Analysis

I would like to order

Product name: IgA Nephropathy Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/IBC8DFAC5250EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IBC8DFAC5250EN.html>